Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea

被引：116

作者：

Kim, JJ

Reddy, R

Lee, M

Kim, JG

El-Zaatari, FAK

Osato, MS

Graham, DY

Kwon, DH

机构：

[1] Baylor Coll Med, Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA

[2] Korea Univ, Coll Med, Seoul, South Korea

[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2001年 / 47卷 / 04期

关键词：

D O I：

10.1093/jac/47.4.459

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Antibiotic resistance in Helicobacter pylori varies according to geographical region. We studied the primary resistance rates among 652 H. pylori isolated from Korea in relation to collection date, disease presentation, age and gender. Resistance rates were 40.6% (metronidazole), 5.9% (clarithromycin), 5.3% (tetracycline), 0% (amoxycillin), 1.5% (furazolidone) and 1.5% (nitrofurantoin). Resistance to metronidazole and clarithromycin increased from 1994 to 1999 (from 33.3 to 47.7% and 4.8 to 7.7%, respectively), but the differences only reached significance when rates of metronidazole resistance in women were compared with those in men (48.6 versus 36.9%).

引用

收藏

页码：459 / 461

页数：3

相关论文

共 10 条

[1] Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin -: Influence on treatment outcome [J].

Adamek, RJ ;

Suerbaum, S ;

Pfaffenbach, B ;

Opferkuch, W .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (03) :386-389

[2] Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori [J].

Kwon, DH ;

El-Zaatari, FAK ;

Kato, M ;

Osato, MS ;

Reddy, R ;

Yamaoka, Y ;

Graham, DY .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2133-2142

[3] The MACH2 study:: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies [J].

Lind, T ;

Mégraud, F ;

Unge, P ;

Bayerdörffer, E ;

O'Morain, C ;

Spiller, R ;

van Zanten, SV ;

Bardhan, KD ;

Hellblom, M ;

Wrangstadh, M ;

Zeijlon, L ;

Cederberg, C .

GASTROENTEROLOGY, 1999, 116 (02) :248-253

[4] Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain [J].

LopezBrea, M ;

Domingo, D ;

Sanchez, I ;

Alarcon, T .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (02) :279-281

[5]

Malaty HM, 1996, AM J EPIDEMIOL, V143, P257, DOI 10.1093/oxfordjournals.aje.a008736

[6] Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial:: the MACH 2 study [J].

Mégraud, F ;

Lehn, N ;

Lind, T ;

Bayerdörffer, E ;

O'Morain, C ;

Spiller, R ;

Unge, P ;

Van Zanten, SV ;

Wrangstadh, M ;

Burman, CF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) :2747-2752

[7] Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil [J].

Mendonça, S ;

Ecclissato, C ;

Sartori, MS ;

Godoy, APO ;

Guerzoni, RA ;

Degger, M ;

Pedrazzoli, J .

HELICOBACTER, 2000, 5 (02) :79-83

[8] Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori rdxA plus (nitroreductase) gene [J].

Sisson, G ;

Jeong, JY ;

Goodwin, A ;

Bryden, L ;

Rossler, N ;

Lim-Morrison, S ;

Raudonikiene, A ;

Berg, DE ;

Hoffman, PS .

JOURNAL OF BACTERIOLOGY, 2000, 182 (18) :5091-5096

[9] Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands [J].

vanderWouden, EJ ;

vanZwet, AA ;

Thijs, JC ;

Vosmaer, GDC ;

Oom, JAJ ;

deJong, A ;

Kleibeuker, JH .

EMERGING INFECTIOUS DISEASES, 1997, 3 (03) :385-389

[10]

YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65